-
Zanubrutinib, sold
under the
brand name Brukinsa, is an
anticancer medication used for the
treatment of
mantle cell
lymphoma (MCL), Waldenström's macroglobulinemia...
- pharmaceuticals,
including tislelizumab, a
checkpoint inhibitor, and
zanubrutinib, a Bruton's
tyrosine kinase inhibitor. On 14 November, 2024 the company...
-
Bruton tyrosine kinase inhibitors (BTKi), such as such as ibrutinib,
zanubrutinib, and
acalabrutinib B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax, plus...
-
Chronic lymphocytic leukemia (CLL) and
Small lymphocytic lymphoma (SLL)
Zanubrutinib (Brukinsa) for
mantle cell lymphoma,
chronic lymphocytic leukemia (CLL)...
-
diagnosis and/or
start of
zanubrutinib.
Median follow-up time was 7.7 months, all
patients were
alive and
still on
zanubrutinib treatment. Of 12 patients...
-
Cobimetinib Selumetinib Trametinib EML4-ALK
Crizotinib Entrectinib Lorlatinib Bruton's (BTK)
Acalabrutinib Ibrutinib Orelabrutinib Pirtobrutinib Zanubrutinib...
- alone.
Autologous bone
marrow transplantation is a
treatment option.
Zanubrutinib,
another BTK inhibitor, is
indicated for the
treatment of
adults with...
- 5'-Guanidinonaltrindole (5'-GNTI) 6'-Guanidinonaltrindole (6'-GNTI)
Zanubrutinib This set
index page
lists chemical structure articles ****ociated with...
-
kinase inhibitors received were
ibrutinib (67%),
acalabrutinib (30%), and
zanubrutinib (8%); 83% had
discontinued their last Bruton's
tyrosine kinase inhibitor...
-
duration is
short and
patients typically relapse. In
November 2019,
zanubrutinib (Brukinsa) was
approved in the
United States with an
indication for the...
